Search

Ipsen SA.

Gesloten

SectorFinanciƫn

121.3 2.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

118.5

Max

121.8

Belangrijke statistieken

By Trading Economics

Inkomsten

220M

334M

Verkoop

-2.9M

1.8B

K/W

Sectorgemiddelde

21.173

27.91

Dividendrendement

1.22

Winstmarge

18.354

Werknemers

5,358

EBITDA

-73M

637M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+20.42% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.22%

4.01%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

111M

9.4B

Vorige openingsprijs

119.2

Vorige sluitingsprijs

121.3

Nieuwssentiment

By Acuity

34%

66%

113 / 528 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Ipsen SA. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 dec 2024, 07:05 UTC

Marktinformatie

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Ipsen SA. Prognose

Koersdoel

By TipRanks

20.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 136.2Ā EURĀ  20.42%

Hoogste 148Ā EUR

Laagste 120Ā EUR

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ipsen SA. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technische score

By Trading Central

99.85 / 104Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

113 / 528 Rangschikking in Financiƫn

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat